SLDB

Solid Biosciences Inc

6.18

Nov 05 • 3:59 PM ET -0.34 (-5.21%)

6.18

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Nov 04, 6:45 PMSolid Biosciences posts Q3 2026 EPS -$0.36 on zero revenue, beats EPS and revenue estimates, cash runway $348.9M into H1 2028

Peers: SRPT RGNX DYN WVE CAPR LXEO EWTX RCKT TRDA PTCT

| Held by: VTI IWM XBI VXF IBB DFAS FESM VTWO IWN IWO

Scroll to Statements

Index	RUT
Market Cap	662.65M
Enterprise Value	304.49M
Income	-207.10M
Sales	0.00M
Book/sh	3.56
Cash/sh	3.53
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	121
IPO	Jan 26, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.74
P/C	1.75
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	13.82
Current Ratio	13.82
Debt/Eq	0.05
LT Debt/Eq	0.05
Option/Short	Yes / Yes

EPS (ttm)	-1.91
EPS next Y	-1.59
EPS next Q	-0.39
EPS this Y	16.26%
EPS next Y	4.73%
EPS next 5Y	18.94%
EPS past 3/5Y	41.79% 39.94%
Sales past 3/5Y	- -
EPS Y/Y TTM	31.81%
Sales Y/Y TTM	-
EPS Q/Q	9.06%
Sales Q/Q	-
Earnings	Nov 04 AMC
EPS/Sales Surpr.	12.04% -

Insider Own	18.41%
Insider Trans	-0.02%
Inst Own	90.72%
Inst Trans	13.03%
ROA	-56.83%
ROE	-65.50%
ROIC	-52.83%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	0.47%
SMA50	-18.17%
SMA200	-19.43%
Trades

Shs Outstand	105.13M
Shs Float	87.48M
Short Float	14.06%
Short Ratio	10.48
Short Interest	12.30M
52W High	11.45 -46.03%
52W Low	3.79 63.06%
Volatility	7.33% 7.32%
ATR (14)	0.45
RSI (14)	43.95
Beta	2.63
Rel Volume	1.22
Avg Volume	1.17M
Volume	1,436,090

Perf Week	-3.29%
Perf Month	-9.78%
Perf Quarter	-26.34%
Perf Half Y	-12.59%
Perf YTD	9.57%
Perf Year	57.25%
Perf 3Y	117.61%
Perf 5Y	-82.54%
Perf 10Y	-
Recom	1.00
Target Price	18.71
Prev Close	6.52
Price	6.18
Change %	-5.21%

Consensus

Strong Buy

Avg. Price Target

$18.71

Implied Upside

+202.8%

Analysts16incl. previous ratings

Rating Distribution16 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 15, 2026	Initiated	UUBS	Buy	$20	+223.6%
Sep 16, 2026	Initiated	RRBC Capital Mkts	Outperform	$18	+191.3%
Aug 21, 2026	Resumed	TTruist	Buy	$20	+223.6%
Mar 20, 2026	Initiated	GGuggenheim	Buy	$26	+320.7%
Dec 04, 2025	Initiated	NNeedham	Buy	$16	+158.9%
Jun 26, 2025	Initiated	CCitigroup	Buy	$14	+126.5%
Jan 08, 2025	Initiated	TTruist	Buy	$16	+158.9%
Dec 13, 2024	Initiated	WWedbush	Outperform	$16	+158.9%
Dec 10, 2024	Initiated	JJMP Securities	Mkt Outperform	$15	+142.7%
Jul 15, 2024	Upgrade	JJP Morgan	Neutral → Overweight	$10 → $15	+142.7%
Jun 24, 2024	Upgrade	LLeerink Partners	Market Perform → Outperform	$12	+94.2%
May 31, 2024	Resumed	PPiper Sandler	Overweight	$20	+223.6%
Mar 28, 2024	Initiated	WWilliam Blair	Outperform	$40	+547.2%
Mar 15, 2024	Initiated	CCitigroup	Buy	$16	+158.9%
Mar 14, 2024	Upgrade	PPiper Sandler	Neutral → Overweight	$8 → $20	+223.6%
Dec 08, 2023	Initiated	HH.C. Wainwright	Buy	$9	+45.6%
Jul 12, 2021	Initiated	PPiper Sandler	Neutral	$6	-2.9%
May 27, 2021	Initiated	JJefferies	Buy	$7	+13.3%
Mar 16, 2021	Upgrade	SSVB Leerink	Mkt Perform → Outperform	$3 → $15	+142.7%
Mar 09, 2021	Initiated	BBarclays	Overweight	$13	+110.4%

Today 08:00AM	Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference (GlobeNewswire) -5.21%
Nov-04-26 04:07PM	Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Oct-26-26 08:00AM	Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich's Ataxia (GlobeNewswire)
Oct-20-26 08:00AM	Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026 (GlobeNewswire) +8.11%
Oct-01-26 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
Sep-02-26 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-06-26 04:08PM	Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Jun-08-26 03:00AM	BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors (TMX Newsfile)
Jun-01-26 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.48%
08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
May-12-26 04:08PM	Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
May-07-26 08:00AM	Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy (GlobeNewswire)
May-01-26 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-30-26 08:00AM	Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy (GlobeNewswire)
Apr-28-26 08:00AM	Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
08:00AM	Loading…
Apr-07-26 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Mar-19-26 04:12PM	Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-11-26 01:01PM	Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial (GlobeNewswire) -5.68%
Mar-09-26 01:32PM	What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? (Benzinga) +18.81%
Mar-06-26 08:31AM	Solid Biosciences Announces Oversubscribed $240 Million Private Placement (GlobeNewswire) +20.32%
08:30AM	Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (GlobeNewswire)
Mar-02-26 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-15-26 05:35AM	Solid Biosciences Highlights FDA Path for SGT-003 DMD Study, Shares Early Friedreichs Ataxia Update (MarketBeat)
Feb-09-26 08:00AM	Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy (GlobeNewswire) +5.21%
Feb-06-26 08:00AM	Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-26-26 02:49PM	Sarepta Stock Climbs. 3-Year Study Results for Elevidys Bring Hope. (Barrons.com)
Jan-16-26 09:08AM	Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? (Zacks)
Jan-15-26 12:58PM	JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success (Pharmaceutical Technology)
Jan-13-26 04:15PM	Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101 (GlobeNewswire) +12.60%
Jan-12-26 04:15PM	Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia (GlobeNewswire)
08:05AM	Loading…
08:05AM	Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia (GlobeNewswire)
Jan-06-26 08:00AM	Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-26 04:15PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-16-25 04:51PM	Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services (GlobeNewswire) -7.56%
Dec-15-25 11:10PM	Sarepta's Elevidys Safety Concerns Open Major Opportunity for Solid Biosciences' (SLDB) SGT-003 in Duchenne Therapy (Insider Monkey)
Dec-08-25 08:00AM	Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum (GlobeNewswire)
Dec-02-25 06:54AM	Solid Biosciences' SGT-212 gains FDA rare paediatric disease status (Pharmaceutical Business Review)
Dec-01-25 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia (GlobeNewswire)
Nov-17-25 08:00AM	Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101 (GlobeNewswire)
Nov-11-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire) +9.16%
Nov-06-25 08:00AM	Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy (GlobeNewswire) +7.25%
Nov-04-25 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -15.29% -10.78%
Nov-03-25 04:05PM	Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions (GlobeNewswire)
Oct-30-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Oct-01-25 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Solid Biosciences to Present at Upcoming Scientific Meetings (GlobeNewswire)
Sep-25-25 08:00AM	Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting (GlobeNewswire) -5.13%
Sep-23-25 08:00AM	Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101 (GlobeNewswire)
Sep-18-25 09:10AM	Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics (PR Newswire)
Aug-28-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-12-25 04:07PM	Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) +10.60%
03:33PM	Brutal 2025 for Sarepta-Analysts Still Call for 179% Upside (MarketBeat)
Aug-01-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-23-25 08:00AM	Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (GlobeNewswire) +8.51%
Jul-21-25 08:30AM	Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors (GlobeNewswire)
Jul-09-25 10:17AM	Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with 'Buy' Rating and $14 PT (Insider Monkey) +5.34%
Jul-08-25 04:05PM	Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (GlobeNewswire) +6.72%
Jul-01-25 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.54% +5.87%
Jun-26-25 09:49AM	General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls (The Fly)
Jun-18-25 11:39AM	Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences (MarketBeat)
Jun-03-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-28-25 08:00AM	Solid Biosciences to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire) +7.24%
May-15-25 04:06PM	Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) +6.95%
May-01-25 04:00PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.27% +18.08%
Apr-30-25 08:00AM	Solid Biosciences to Participate at The Citizens Life Sciences Conference (GlobeNewswire) +8.52%
Apr-29-25 08:00AM	Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting (GlobeNewswire) -5.57%
Apr-08-25 04:50PM	Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space (Seeking Alpha) -9.18%
07:30AM	Can Solid Biosciences Challenge Sarepta in the DMD Market? (MarketBeat)
Apr-07-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire) -5.62%
Apr-01-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.89%
07:00AM	Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors (GlobeNewswire)
Mar-26-25 12:31PM	5 Reasons To Buy Regenxbio Right Now (SeekingAlpha) -5.12%
Mar-14-25 10:29PM	Solid Biosciences Inc. (SLDB): Among Top Insider Purchases Last Month (Insider Monkey) +5.30%
Mar-12-25 08:00AM	Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (GlobeNewswire)
Mar-07-25 09:55AM	Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade (Zacks)
Mar-06-25 04:16PM	Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-05-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire) +8.47%
Mar-04-25 08:33PM	Is Solid Biosciences Inc. (SLDB) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey)
04:07PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-25 08:02AM	Solid Biosciences stock soars on early success in DMD gene therapy trial (Clinical Trials Arena) +22.08%
Feb-18-25 07:00AM	Solid Biosciences Announces Pricing of Underwritten Offering (GlobeNewswire) +31.51%
06:45AM	Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003 (GlobeNewswire)
06:36AM	Solid says early data suggest differentiated Duchenne gene therapy (BioPharma Dive)
Feb-09-25 06:12AM	Analysts Predict Up to ~450% Surge for These 2 Strong Buy Penny Stocks (TipRanks)
Feb-04-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-21-25 08:30AM	Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia (GlobeNewswire)
Jan-15-25 04:05PM	Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines (GlobeNewswire)
Jan-08-25 04:05PM	Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -8.68%
Jan-07-25 04:15PM	Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia (GlobeNewswire)
Jan-06-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-23-24 04:05PM	Solid Biosciences Added to the Nasdaq Biotechnology Index (GlobeNewswire)
Dec-13-24 01:52PM	Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst (Benzinga)
Dec-04-24 08:05AM	Solid Biosciences reports inducement grant under Nasdaq listing rule (TipRanks)
08:00AM	Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies (GlobeNewswire)
Dec-03-24 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.54%
Nov-26-24 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-14-24 08:00AM	Solid Biosciences to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-06-24 04:05PM	Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.03%
Nov-04-24 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brooks Gabriel	Chief Medical Officer	Oct 19 '26	Sale	5.62	4,374	24,582	97,241	Oct 20 04:05 PM
Cumbo Alexander	President and CEO	Feb 18 '26	Sale	5.82	16,644	96,923	235,405	Feb 18 09:38 PM
Brooks Gabriel	Officer	Feb 18 '26	Proposed Sale	5.82	5,563	32,395		Feb 18 09:35 PM
Cumbo Alexander	Officer	Feb 18 '26	Proposed Sale	5.82	16,644	96,923		Feb 18 09:35 PM
Hanrahan Jessie	Chief Regulatory Officer	Feb 18 '26	Sale	5.82	4,134	24,074	74,318	Feb 18 09:34 PM
Hanrahan Jessie	Officer	Feb 18 '26	Proposed Sale	5.82	4,134	24,074		Feb 18 09:33 PM
Ganot Ilan	Director	Feb 18 '26	Sale	5.82	2,658	15,478	27,474	Feb 18 09:32 PM
Herzich Paul	Officer	Feb 18 '26	Proposed Sale	5.82	3,616	21,057		Feb 18 09:32 PM
Ganot Ilan	Director	Feb 18 '26	Proposed Sale	5.92	2,658	15,748		Feb 18 09:31 PM
Herzich Paul	Chief Technology Officer	Feb 18 '26	Sale	5.82	3,616	21,057	72,638	Feb 18 09:31 PM
Howton David T	Chief Operating Officer	Feb 18 '26	Sale	5.82	7,469	43,494	105,077	Feb 18 09:31 PM
Howton David T	Officer	Feb 18 '26	Proposed Sale	5.82	7,469	43,494		Feb 18 09:30 PM
Tan Kevin	Officer	Feb 18 '26	Proposed Sale	5.82	5,404	31,469		Feb 18 09:28 PM
Tan Kevin	CFO & Treasurer	Feb 18 '26	Sale	5.82	5,404	31,469	99,422	Feb 18 09:25 PM
Howton David T	Chief Operating Officer	Feb 04 '26	Sale	6.44	18,894	121,713	97,859	Feb 06 06:05 PM
Cumbo Alexander	President and CEO	Feb 04 '26	Sale	6.44	48,913	315,093	222,018	Feb 06 06:01 PM
Ganot Ilan	Director	Feb 04 '26	Sale	6.44	7,205	46,414	25,271	Feb 06 06:01 PM
Tan Kevin	CFO & Treasurer	Feb 04 '26	Sale	6.44	14,783	95,231	94,201	Feb 06 06:00 PM
Brooks Gabriel	Chief Medical Officer	Feb 04 '26	Sale	6.44	12,616	81,271	84,092	Feb 06 05:59 PM
Hanrahan Jessie	Chief Regulatory Officer	Feb 04 '26	Sale	6.44	12,348	79,545	70,327	Feb 06 05:57 PM
Herzich Paul	Chief Technology Officer	Feb 04 '26	Sale	6.44	10,905	70,249	69,067	Feb 06 05:56 PM
Tan Kevin	Officer	Feb 04 '26	Proposed Sale	6.44	14,783	95,227		Feb 04 07:48 PM
Herzich Paul	Officer	Feb 04 '26	Proposed Sale	6.44	10,905	70,247		Feb 04 07:46 PM
Ganot Ilan	Director	Feb 04 '26	Proposed Sale	6.44	7,205	46,412		Feb 04 07:45 PM
Cumbo Alexander	Officer	Feb 04 '26	Proposed Sale	6.44	48,913	315,080		Feb 04 07:44 PM
Howton David T	Officer	Feb 04 '26	Proposed Sale	6.44	18,894	121,708		Feb 04 07:42 PM
Hanrahan Jessie	Officer	Feb 04 '26	Proposed Sale	6.44	12,348	79,541		Feb 04 07:40 PM
Brooks Gabriel	Officer	Feb 04 '26	Proposed Sale	6.44	12,616	81,268		Feb 04 07:37 PM
Tan Kevin	CFO & Treasurer	Feb 02 '26	Sale	6.44	26,837	172,747	108,984	Feb 02 08:18 PM
Cumbo Alexander	President and CEO	Feb 02 '26	Sale	6.44	80,258	516,613	270,931	Feb 02 08:16 PM
Hanrahan Jessie	Chief Regulatory Officer	Feb 02 '26	Sale	6.44	26,535	170,803	82,675	Feb 02 08:15 PM
Brooks Gabriel	Chief Medical Officer	Feb 02 '26	Sale	6.44	28,335	182,390	96,708	Feb 02 08:14 PM
Howton David T	Chief Operating Officer	Feb 02 '26	Sale	6.44	37,771	243,128	116,753	Feb 02 08:12 PM
Herzich Paul	Chief Technology Officer	Feb 02 '26	Sale	6.44	26,250	168,969	79,972	Feb 02 08:09 PM
Hanrahan Jessie	Officer	Feb 02 '26	Proposed Sale	6.44	26,535	170,803		Feb 02 08:07 PM
Brooks Gabriel	Officer	Feb 02 '26	Proposed Sale	6.44	28,335	182,390		Feb 02 08:05 PM
Tan Kevin	Officer	Feb 02 '26	Proposed Sale	6.44	26,837	172,747		Feb 02 08:04 PM
Cumbo Alexander	Officer	Feb 02 '26	Proposed Sale	6.44	80,258	516,613		Feb 02 08:03 PM
Howton David T	Officer	Feb 02 '26	Proposed Sale	6.44	37,771	243,128		Feb 02 08:01 PM
Herzich Paul	Officer	Feb 02 '26	Proposed Sale	6.44	26,250	168,969		Feb 02 07:59 PM
Ganot Ilan	Director	Jan 28 '26	Sale	6.59	191	1,259	17,476	Jan 30 04:05 PM
Tan Kevin	CFO & Treasurer	Jan 13 '26	Sale	5.27	5,704	30,060	46,100	Jan 13 05:02 PM
Tan Kevin	Officer	Jan 13 '26	Proposed Sale	5.27	5,704	30,060		Jan 13 05:00 PM
Ganot Ilan	Director	Jan 05 '26	Sale	5.43	1,053	5,718	17,278	Jan 06 06:52 PM
Howton David T	Chief Operating Officer	Dec 03 '25	Sale	5.11	4,932	25,203	32,908	Dec 04 04:22 PM
Cumbo Alexander	President and CEO	Dec 03 '25	Sale	5.11	10,808	55,229	81,388	Dec 04 04:20 PM
Hanrahan Jessie	Chief Regulatory Officer	Dec 03 '25	Sale	5.11	4,483	22,908	26,660	Dec 04 04:19 PM
Herzich Paul	Chief Technology Officer	Dec 03 '25	Sale	5.11	2,701	13,802	26,622	Dec 04 04:17 PM
Cumbo Alexander	Officer	Dec 03 '25	Proposed Sale	5.11	10,808	55,229		Dec 03 05:07 PM
Ganot Ilan	Director	Nov 10 '25	Sale	4.12	3,278	13,505	95,412	Nov 13 04:05 PM

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

C.P.A.Mr. Ian F. Smith A.C.A.

PresidentMr. Alexander G. Cumbo

Co-founderMr. Ilan Ganot

J.D.Mr. David Tyronne Howton Jr.

Chief Medical OfficerDr. Gabriel Brooks M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SLDB

Solid Biosciences Inc

Upgrade your Finviz experience